6 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Within triple-negative breast cancer, IM is a historical RNA profile influenced by infiltrating immune cells. It is different from a histological lymphocyte count or a PD-L1 test, and does not by itself predict benefit from immunotherapy.
The original TNBCtype IM category was enriched for immune-cell and signalling programmes. In the 2016 refinement, histological lymphocyte content tracked the IM RNA signal. IM and MSL were removed as separate tumour-focused labels in TNBCtype-4 and samples were reassigned using their next-best tumour-profile correlation; immune biology was not discarded.
A bulk RNA immune signature, a stromal tumour-infiltrating lymphocyte assessment and PD-L1 immunohistochemistry measure different features with different methods and units. They are not equivalent tests. Burstein BLIA/BLIS and the Fudan IHC-based IM category also belong to other classifiers; sharing an immune-related name does not harmonise their groups. Treatment-linked testing must retain the exact product, scoring rule and clinical setting.
| Setting | Approach | Guideline |
|---|---|---|
| Metastatic, PD-L1 CPS 10 or more | Pembrolizumab with chemotherapy (KEYNOTE-355; NICE TA801) or with sacituzumab govitecan (ASCENT-04); the rows on the parent page. | not mapped |